We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Curious about CVS Health (CVS) Q3 Performance? Explore Wall Street Estimates for Key Metrics
Read MoreHide Full Article
Wall Street analysts forecast that CVS Health (CVS - Free Report) will report quarterly earnings of $1.57 per share in its upcoming release, pointing to a year-over-year decline of 29%. It is anticipated that revenues will amount to $92.87 billion, exhibiting an increase of 3.5% compared to the year-ago quarter.
The current level reflects an upward revision of 5.1% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
Bearing this in mind, let's now explore the average estimates of specific CVS Health metrics that are commonly monitored and projected by Wall Street analysts.
It is projected by analysts that the 'Revenue- Pharmacy & Consumer Wellness Segment' will reach $30.93 billion. The estimate indicates a change of +7.2% from the prior-year quarter.
The consensus among analysts is that 'Net revenue- Health Services segment' will reach $42.32 billion. The estimate indicates a year-over-year change of -9.7%.
Analysts predict that the 'Revenue- Health Care Benefits' will reach $32.13 billion. The estimate suggests a change of +22.2% year over year.
Analysts forecast 'Revenue- Pharmacy & Consumer Wellness Segment- Other' to reach $550.20 million. The estimate suggests a change of +4.6% year over year.
Analysts expect 'Medical benefit ratio (MBR)' to come in at 91.6%. Compared to the present estimate, the company reported 85.7% in the same quarter last year.
The combined assessment of analysts suggests that 'Medical membership - Total' will likely reach 27.03 million. The estimate is in contrast to the year-ago figure of 25.69 million.
The average prediction of analysts places 'Medical membership - Insured - Medicare Supplement' at $1.30 billion. Compared to the current estimate, the company reported $1.35 billion in the same quarter of the previous year.
The collective assessment of analysts points to an estimated 'Medical membership - ASC - Commercial' of 14.1 million. The estimate is in contrast to the year-ago figure of 14.08 million.
The consensus estimate for 'Medical membership - Insured - Commercial' stands at 4.7 million. Compared to the current estimate, the company reported 4.2 million in the same quarter of the previous year.
According to the collective judgment of analysts, 'Pharmacy claims processed' should come in at 480.07 million. The estimate is in contrast to the year-ago figure of 579.6 million.
Analysts' assessment points toward 'Medical membership - Commercial - Total' reaching 18.8 million. The estimate compares to the year-ago value of 18.27 million.
Based on the collective assessment of analysts, 'Medicare Prescription Drug Plan (standalone)' should arrive at 4.89 million. The estimate compares to the year-ago value of 6.09 million.
Over the past month, CVS Health shares have recorded returns of -10.3% versus the Zacks S&P 500 composite's -1% change. Based on its Zacks Rank #4 (Sell), CVS will likely underperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Curious about CVS Health (CVS) Q3 Performance? Explore Wall Street Estimates for Key Metrics
Wall Street analysts forecast that CVS Health (CVS - Free Report) will report quarterly earnings of $1.57 per share in its upcoming release, pointing to a year-over-year decline of 29%. It is anticipated that revenues will amount to $92.87 billion, exhibiting an increase of 3.5% compared to the year-ago quarter.
The current level reflects an upward revision of 5.1% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
Bearing this in mind, let's now explore the average estimates of specific CVS Health metrics that are commonly monitored and projected by Wall Street analysts.
It is projected by analysts that the 'Revenue- Pharmacy & Consumer Wellness Segment' will reach $30.93 billion. The estimate indicates a change of +7.2% from the prior-year quarter.
The consensus among analysts is that 'Net revenue- Health Services segment' will reach $42.32 billion. The estimate indicates a year-over-year change of -9.7%.
Analysts predict that the 'Revenue- Health Care Benefits' will reach $32.13 billion. The estimate suggests a change of +22.2% year over year.
Analysts forecast 'Revenue- Pharmacy & Consumer Wellness Segment- Other' to reach $550.20 million. The estimate suggests a change of +4.6% year over year.
Analysts expect 'Medical benefit ratio (MBR)' to come in at 91.6%. Compared to the present estimate, the company reported 85.7% in the same quarter last year.
The combined assessment of analysts suggests that 'Medical membership - Total' will likely reach 27.03 million. The estimate is in contrast to the year-ago figure of 25.69 million.
The average prediction of analysts places 'Medical membership - Insured - Medicare Supplement' at $1.30 billion. Compared to the current estimate, the company reported $1.35 billion in the same quarter of the previous year.
The collective assessment of analysts points to an estimated 'Medical membership - ASC - Commercial' of 14.1 million. The estimate is in contrast to the year-ago figure of 14.08 million.
The consensus estimate for 'Medical membership - Insured - Commercial' stands at 4.7 million. Compared to the current estimate, the company reported 4.2 million in the same quarter of the previous year.
According to the collective judgment of analysts, 'Pharmacy claims processed' should come in at 480.07 million. The estimate is in contrast to the year-ago figure of 579.6 million.
Analysts' assessment points toward 'Medical membership - Commercial - Total' reaching 18.8 million. The estimate compares to the year-ago value of 18.27 million.
Based on the collective assessment of analysts, 'Medicare Prescription Drug Plan (standalone)' should arrive at 4.89 million. The estimate compares to the year-ago value of 6.09 million.
View all Key Company Metrics for CVS Health here>>>
Over the past month, CVS Health shares have recorded returns of -10.3% versus the Zacks S&P 500 composite's -1% change. Based on its Zacks Rank #4 (Sell), CVS will likely underperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>